Sat 9/21/2019 04:54 ET
DJIA26935.07158.920.59%TELCO190.202.281.20%GOLD1524.0517.831.17%Shanghai3004.485.110.17%
S&P 5002992.0314.660.49%BANKS458.052.430.53%OIL58.410.220.38%BITCOIN10163.0314.230.14%
NASDAQ8117.6764.940.80%PHARM562.426.131.09%US/EU1.100.000.00%Futures2989.6218.240.61%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Idera Pharmaceuticals - IDRA   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add IDRA
  
From: singhtelecom (Rep: 959)Date: 05/04/2019 02:05
Forum: Idera Pharmaceuticals - Msg #788Thread #674080084 (Rec: 0)
we believe that our available funds will be sufficient to enable perform the following:

(i)

complete enrollment, where applicable, and continue to execute on:

a)

the Phase 1 portion of our ongoing Phase 1/2 clinical trial of tilsotolimod in combination with pembrolizumab in anti-PD1 refractory melanoma (ILLUMINATE-204);

b)

the Phase 2 portion of our ongoing Phase 1/2 clinical trial of tilsotolimod in combination with ipilimumab in anti-PD1 refractory melanoma (ILLUMINATE-204);

c)

the Phase 3 clinical trial of tilsotolimod in combination with ipilimumab for the treatment of anti-PD1 refractory metastatic melanoma (ILLUMINATE-301); and

d)

the Phase 1b monotherapy clinical trial of tilsotolimod in multiple refractory tumor types (ILLUMINATE-101);

(ii)

initiate our Phase 2 study of tilsotolimod in combination with nivolumab and ipilimumab for the treatment of certain solid tumors (ILLUMINATE-206) ;

(iii)

fund certain investigator initiated clinical trials of tilsotolimod; and

(iv)

maintain our current level of general and administrative expenses in order to support the business .

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser singhtelecom: Reward | Watch | IgnoreIDRA: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add IDRA
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.